Sitemap

» Frontpage

Human Health

» Clinical Studies
» For patients
» Human Health
» Links
» Products

Animal Health

» Animal Health
» Clinical Studies
» For companion animal owners
» For veterinarians
» Links
» Products

Management

» Annette Ljungmark (born 1950)
» Hans Sundin (born 1945)
» Julian Aleksov (born 1965)
» Weine Nejdemo (born 1948)

Department Directors

» Amir Tatarevic
» Annette Ljungmark
» Dzianis Babrou
» Hans Sundin
» Henrik von Euler
» Igor Lokot
» John Cosby
» Malin Schenerfelt
» Margareta Eriksson
» Maria Lundén
» Maria Nylander
» Weine Nejdemo

Board of directors

» Bo Cederstrand (born 1939)
» Horst Domdey (born 1951)
» Jan Lundberg (born 1946)
» Joel Citron (born 1962)
» Julian Aleksov (born 1965)
» Martin Nicklasson (born 1955)

Annual General Meeting

» Summary of the Annual General Meeting 2006
» Summary of the Annual General Meeting 2007
» Summary of the Annual General Meeting 2008
» Summary of the Annual General Meeting 2010
» Summary of the Annual General Meeting 2011

Corporate governance

» Annual General Meetings
» Articles of Association
» Auditor
» Board of Directors
» Chairman of the Board
» Corporate Governance
» Corporate Governance reports
» Department Directors
» Management
» Nomination committee
» Option program
» Work plan for the Board of Directors

The share

» Shareholders
» The share

Investor relations

» Analyses
» Calendar
» Current reports
» Disclaimer issue prospectus
» Investor Relations
» Subscribe

About Oasmia

» About Oasmia
» History
» Organization
» Production
» Research & development
» Vision & goals

Media contact

» Image bank
» Media contact

Job vacancies

» Would you like to work with us?

Contact us

» Contact information

Pages

» Glossary

Press releases

» A big step for Oasmia in Barcelona
» Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal® Vet, a New Chemotherapeutic Agent for Dogs
» American veterinarians see the future in drug candidate Paclical® Vet
» Björn Björnsson new Chairman of the Board of Oasmia Pharmaceutical AB
» Björn Björnsson nominated as new Member of the Board in Oasmia Pharmaceutical AB
» Clinical study with Doxophos® Vet approved
» Communiqué from Annual General Meeting
» Communiqué from Annual General Meeting 2010
» Communiqué from Annual General Meeting 2011
» Communiqué from Extraordinary General Meeting
» Convincing results for Oasmia's Cancer Candidate Paclical® Vet
» Directed new share issue successfully completed – nxt2b new major shareholder
» EMEA final advice for start of Oasmia's Paclical® Phase III program
» Enrolment complete in Phase III study with Paclical®
» FDA grants Oasmia Pharmaceutical Expedited Review Status (ERS) for Paclical® Vet
» FDA grants Paccal® Vet Minor Use designation for mammary tumors
» FDA grants Paccal® Vet Minor Use designation for squamous cell carcinoma
» Great interest for Oasmia in Budapest
» Interim report May 1 - July 31 2009
» Interim report May 1 - July 31 2010
» Interim report May 1 - July 31 2011
» Interim report May 1 - Oct 31 2010
» Interim report May 1 - October 31 2011
» Interim report May 1 2010 - Jan. 31 2011
» Interim report May 1, 2009 - January 31, 2010
» Interim report May 2008 - January 2009
» Last patient out (LPO) for Paccal® Vet Phase III study
» New drug for treatment of cancer in dog
» Notice of Annual General Meeting
» Notice of the Annual General Meeting 2011
» Oasmia and Orion Corporation jointly end Paclical® agreement
» Oasmia announces launch of private placement of new shares
» Oasmia appoints E. Öhman J:or Fondkommission AB as market maker and financial advisor as well as forwards the publication of the interim report
» Oasmia changes marketplace
» Oasmia changes report publication date
» Oasmia closes agreement with Nippon Zenyaku Kogyo.
» OASMIA CONFIRMS ORPHAN DRUG DESIGNATION FOR OAS-PAC-100 (PACLITAXEL MICELLAR)
» Oasmia enters new important license agreement for Paclical® Vet with Orion Corporation
» Oasmia expands license agreement for Paclical® Vet to include European-wide rights
» Oasmia initiates clinical studies with the new pharmaceutical candidate Doxophos® Vet for treatment of cancer in dogs.
» Oasmia is admitted to trading on NASDAQ OMX Stockholm
» OASMIA OBTAINS ORPHAN DRUG DESIGNATION FOR OAS-PAC-100 (PACLITAXEL MICELLAR)
» OASMIA PHARMACEUTICAL AB (publ.) CALL TO EXTRAORDINARY GENERAL MEETING
» OASMIA PHARMACEUTICAL AB (publ.) Notice of Annual General Meeting 2009
» Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of SEK 239 million
» Oasmia Pharmaceutical AB announces agreement with Baxter Oncology GmbH for large scale commercial manufacturing
» Oasmia Pharmaceutical AB, Sweden and Medison Pharma, Israel announce license and distribution agreement for Paclical® in Israel and Turkey
» Oasmia Pharmaceutical AB, Sweden has applied for listing at Frankfurt Stock Exchange
» Oasmia Pharmaceutical AB, Uppsala, Sweden, carries out private placement
» Oasmia Pharmaceutical AB:s listing on the Frankfurt Stock Exchange approved
» Oasmia Pharmaceutical aims for worldwide registration with a pivotal study on Paccal® Vet
» Oasmia Pharmaceutical announces licensing agreement with Orion Corporation regarding new innovative ovarian cancer drug candidate, Paclical®.
» Oasmia Pharmaceutical appoints Remium as liquidity provider and financial advisor
» Oasmia Pharmaceutical begins the centralized approval procedure for Paccal® Vet with the EMA
» Oasmia Pharmaceutical candidate Paclical® shows promising results in patients with severe cancer.
» Oasmia Pharmaceutical completes rights issue of SEK 238.7 million
» Oasmia Pharmaceutical, Sweden, announces distribution agreement with Abbott Laboratories for Paccal® Vet on the US and Canadian veterinary market.
» Oasmia Pharmaceutical's international multicentre Phase III study on ovarian cancer generates great interest across Europe
» Oasmia presents Paclical® Vet in Budapest
» Oasmia presents Phase III results for Paclical® Vet in Copenhagen
» Oasmia proposes new share issue
» Oasmia publishes Interim Report for May - Oct
» Oasmia publishes Listing Prospectus
» Oasmia publishes the annual report for the fiscal year 2010/2011
» Oasmia S.A. offers background and facts in response to accusations in the media
» Oasmia S.A.’s commitment to subscribe for shares in Oasmia Pharmaceutical AB’s (publ) rights issue
» Oasmia Successfully Concludes Enrolment for Pivotal Study of Mast Cell Tumors in Dogs
» Oasmia Sweden enters into SEK 75 million Standby Equity Distribution Agreement with U.S.-based YA Global Master SPV Ltd.
» Oasmia to NGM Equity
» Oasmia: Clinical study shows good tolerance for Doxophos® Vet
» Oasmia: FDA grants Paccal® Vet Minor Use status
» Oasmia: FDA grants Paclical® Orphan Drug Designation for ovarian cancer in the USA
» Oasmia’s rights issue fully subscribed
» Oasmia's cancer drug one step closer the American market
» Paccal Vet´s Phase III study submitted to FDA for evaluation of clinical efficacy and safety
» Positive Phase III result from the interim analysis of the study in ovarian cancer with Paclical®
» Preliminary analysis indicates that Oasmia's product candidate Paccal® Vet met primary endpoint in Phase III study in dogs with mastocytoma
» Prospectus regarding Oasmia Pharmaceutical's rights issue is now available
» Publication of change in the total number of shares and votes in Oasmia
» Publication of change in the total number of shares and votes in Oasmia
» Solid scientific evidence for Oasmia product candidate Paccal® Vet
» Status – listing of Oasmia
» The Nomination Committee’s proposal regarding Board members in Oasmia Pharmaceutical AB
» The Oasmia Pharmaceutical share is now traded on NASDAQ OMX Stockholm
» The prospectus for Oasmia's new share issue 2009 is now available
» Ticker: Clarification regarding Oasmia SA
» Two thirds of the patients enrolled in the Paclical® Phase III study
» Unique results for cancer drug presented in Cambridge
» Very good clinical results for Paclical®
» Year-end report May 1 2009 - April 30 2010
» Year-end report May 1 2010 - April 30 2011

Latest News (displayed on frontpage)

» Analysis from ECOFIN Global Consulting
» Dr. Kalliwoda Research GmbH presents a new analysis of Oasmia Pharmaceutical AB
bottom